Premedication strategy for weekly paclitaxel

Cancer Investigation

Volumn 20, Issue 5-6, 2002, Pages 666-672

  Quock, Justin ^a   Dea, Gilland ^a   Tanaka, Michael ^a   Gandara, David ^a   Lara, Primo ^a   Lau, Derick ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; AGED; ALGORITHM; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG COST; HEALTH CARE COST; HUMAN; HYPERSENSITIVITY REACTION; INCIDENCE; MAJOR CLINICAL STUDY; PREMEDICATION; PRIORITY JOURNAL; PROPHYLAXIS; PROVOCATION TEST; RETROSPECTIVE STUDY; SOLID TUMOR; ARTICLE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG HYPERSENSITIVITY; FEMALE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H2 ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 0036047702     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120003535     Document Type: Conference Paper

References (20)

1. Rowinsky, E.K.; Onetto, N.; Canetta, R.M.; Arbuck, G. Taxol: The First of the Taxanes, An Important New Class of Antitumor Agents. Semin. Oncol. 1992, 19, 646-662.
2. Ozols, R.F. The Fox Chase Cancer Center Investigators' Workshop and Consensus Conference. Semin. Oncol. 1999, 26 (Suppl. 18), 1-63.
3. Akerly, W.; Sikov, W.M.; Cummings, F.; Safran, H.; Strenger, R.; Marchant, D. Weekly High-Dose Paclitaxel in Metastatic and Locally Advanced Breast Cancer: A Preliminary Report. Semin. Oncol. 1997, 24 (Suppl. 17), 87-90.
4. Chang, A.Y.; Boros, L.; Asbury, R.; Hui, L.; Rubin, J. Dose-Escalation Study of Weekly 1-hour Paclitaxel Administration in Patients with Refractory Cancers. Semin. Oncol. 1997, 24 (Suppl. 17), 69-71.
5. CALGB 9840: A phase III trial of paclitaxel with trastuzumab in metastatic breast cancer. Cancer and Leukemia Group B, 1998.
6. Choy, H.; Browne, M.J. Paclitaxel as a Radiation Sensitizer in Non-Small Cell Lung Cancer. J. Clin. Oncol. 1994, 12, 2682-2686.
7. Choy, H.; Akerley, W.; Safran, H.; et al. Multiinstitutional Phase II Trial of Paclitaxel, Carboplatin, and Concurrent Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. J. Clin. Oncol. 1998, 16, 3316-3322.
8. Lau, D.H.M.; Ryu, J.; Gandara, D.; Morgan, R.; Doroshow, J.; Wilder, R.; Leigh, B. Concurrent Twice-Weekly Paclitaxel and Thoracic Irradiation for Stage III Non-Small Cell Lung Cancer. Semin. Rad. Oncol. 1999, 9 (Suppl. 1), 117-120.
9. Lau, D.; Edelman, M.; Gandara, D.; et al. Concurrent Twice-Weekly Paclitaxel, Weekly Carboplatin and Radiation for Stage III Non-Small Cell Lung Cancer: A Phase II California Cancer Consortium Trial. Proc. Am. Soc. Clin. Oncol. 2000, Abstract.
10. Lau, D.H.; Young, L.J.; Xue, L.; Burke, P.A.; Cheung, A.T. Paclitaxel (Taxol): An Angiogenesis Inhibitor in a Highly Vascularized Transgenic Breast Cancer. Cancer Biother. Radiopharm. 1999, 14, 31-36.
11. ECOG 1199: A phase III study of doxorubicin/cyclophosphamide therapy followed by paclitaxel or docetaxel given weekly or every 3 weeks in patients with axillary node-positive breast cancer. Eastern Cooperative Oncology Group, 1999.
12. Weiss, R.B.; Donehower, R.C.; Wiernik, P.H.; Ohnuma, T.; Gralla, R.J.; Trump, D.L.; Baker, J.R.; Van Echo, D.A. Hypersensitivity Reaction from Taxol. J. Clin. Oncol. 1990, 7, 1263-1268.
13. Olson, J.K.; Sood, A.K.; Srosky, J.I.; Anderson, B.; Buller, R.E. Taxol Hypersensitivity: Rapid Retreatment is Safe and Cost Effective. Gynecol. Oncol. 1998, 68, 25-28.
14. Bookman, M.A.; Kloth, D.D.; Kover, P.E.; Smolinski, S.; Ozols, R.F. Intravenous Prophylaxis for Paclitaxel-Related Hypersensitivity Reactions. Semin. Oncol. 1997, 69 (Suppl. 19), 13-15.
15. Arbuck, S.G.; Christian, M.C.; Fisherman, J.S.; Cazebave, A.; Sarosy, G. ; Suffness, M. Clinical Development of Taxol. Monogr. J. Natl Cancer Inst. 1993, 15, 11-24.
16. Reckzeh, B.; Merte, H.; Pfluger, K.H.; Pfab, R.; Wolf, M.; Havemann, K. Severe Lymphocytopenia and Interstitial Pneumonia in Patients Treated with Paclitaxel and Simultaneous Radiotherapy for Non-Small-Cell Lung Cancer. J. Clin. Oncol. 1996, 14, 1071-1076.
17. Peereboom, D.M.; Donehower, R.C.; Eisenhauer, E.A.; McGuire, W.; Onetto, N.; Hubbard, J.L.; Piccart, M.; Rowinsky, E.K. Successful Re-treatment with Taxol After Major Hypersensitivity Reactions. J. Clin. Oncol. 1993, 5, 885-890.
18. Markman, M.; Kennedy, A.; Webster, K.; Kulp, B.; Peterson, G.; Belinson, J. Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center. J. Clin. Oncol. 2000, 18, 102-105.
19. Quock, J.; Dea, G.; Lim, N.; Tanaka, M.; Gandara, D.; Lau, D. Premedication Strategy for Weekly Paclitaxel Based on Experience with 1608 Infusions of 3- and 4-Week Paclitaxel. Proc. Am. Soc. Clin. Oncol. 1999, 18, 165, Abstract.
20. Lau, D.; Leigh, B.; Gandara, D.; et al. Twice Weekly Paclitaxel and Weekly Carboplatin with Concurrent Thoracic Radiation followed by Carboplatin/Paclitaxel Consolidation for Stage III Non-small-Cell Lung Cancer: A California Cancer Consortium Phase II Trial. J. Clin. Oncol. 2001, 19, 442-447.